MyoKardia, Inc
NEWS
MyoKardia, Inc. was acquired by Bristol Myers Squibb (BMS) in 2020.
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
MyoKardia, Inc. announced the presentation of three abstracts at the upcoming European Society of Cardiology Congress taking place August 31 – September 4, 2019 in Paris, France.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
MyoKardia, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy.
Pre-Application Letters of Intent are Due September 13 for the 2019-2020 Funding Cycle
MyoKardia, Inc. reported financial results for the second quarter ended June 30, 2019.
MyoKardia, Inc., announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019.
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
Continuous Monitoring with Wearable Device Detected Distinct Pulse Wave Patterns in Obstructive Hypertrophic Cardiomyopathy Patients as Compared to Healthy Volunteers
IN THE PRESS